Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42


Brief Report: Durability of the Effect of Financial Incentives on HIV Viral Load Suppression and Continuity in Care: HPTN 065 Study.

El-Sadr WM, Beauchamp G, Hall HI, Torian LV, Zingman BS, Lum G, Elion RA, Buchacz K, Burns D, Zerbe A, Gamble T, Donnell DJ; HPTN 065 Study.

J Acquir Immune Defic Syndr. 2019 Jul 1;81(3):300-303. doi: 10.1097/QAI.0000000000001927.


An expanded HIV screening strategy in the Emergency Department fails to identify most patients with undiagnosed infection: insights from a blinded serosurvey.

Felsen UR, Torian LV, Futterman DC, Stafford S, Xia Q, Allan D, Esses D, Cunningham CO, Weiss JM, Zingman BS.

AIDS Care. 2019 May 30:1-7. doi: 10.1080/09540121.2019.1619663. [Epub ahead of print]


Pathways to HIV Pre-exposure Prophylaxis Among Women Prescribed PrEP at an Urban Sexual Health Clinic.

Park CJ, Taylor TN, Gutierrez NR, Zingman BS, Blackstock OJ.

J Assoc Nurses AIDS Care. 2019 May-Jun;30(3):321-329. doi: 10.1097/JNC.0000000000000070.


Undiagnosed HIV and HCV Infection in a New York City Emergency Department, 2015.

Torian LV, Felsen UR, Xia Q, Laraque F, Rude EJ, Rose H, Cole A, Bocour A, Williams GJ, Bridgforth RF, Forgione LA, Doo H, Braunstein SL, Daskalakis DC, Zingman BS.

Am J Public Health. 2018 May;108(5):652-658. doi: 10.2105/AJPH.2018.304321. Epub 2018 Mar 22.


Expanding Hospital Human Immunodeficiency Virus Testing in the Bronx, New York and Washington, District of Columbia: Results From the HPTN 065 Study.

Branson BM, Chavez PR, Hanscom B, Greene E, McKinstry L, Buchacz K, Beauchamp G, Gamble T, Zingman BS, Telzak E, Naab T, Fitzpatrick L, El-Sadr WM; HIV Prevention Trials Network (HPTN) 065 Study Team.

Clin Infect Dis. 2018 May 2;66(10):1581-1587. doi: 10.1093/cid/cix1053.


Expanded HIV Testing Strategy Leveraging the Electronic Medical Record Uncovers Undiagnosed Infection Among Hospitalized Patients.

Felsen UR, Cunningham CO, Heo M, Futterman DC, Weiss JM, Zingman BS.

J Acquir Immune Defic Syndr. 2017 May 1;75(1):27-34. doi: 10.1097/QAI.0000000000001299.


Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.

Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, Murrell B, Pfeifer N, Nogueira L, Oliveira TY, Learn GH, Cohen YZ, Lehmann C, Gillor D, Shimeliovich I, Unson-O'Brien C, Weiland D, Robles A, Kümmerle T, Wyen C, Levin R, Witmer-Pack M, Eren K, Ignacio C, Kiss S, West AP Jr, Mouquet H, Zingman BS, Gulick RM, Keler T, Bjorkman PJ, Seaman MS, Hahn BH, Fätkenheuer G, Schlesinger SJ, Nussenzweig MC, Klein F.

Nat Med. 2017 Feb;23(2):185-191. doi: 10.1038/nm.4268. Epub 2017 Jan 16.


Combination of Antiretroviral Drugs and Radioimmunotherapy Specifically Kills Infected Cells from HIV-Infected Individuals.

Tsukrov D, McFarren A, Morgenstern A, Bruchertseifer F, Dolce E, Gorny MK, Zolla-Pazner S, Berman JW, Schoenbaum E, Zingman BS, Casadevall A, Dadachova E.

Front Med (Lausanne). 2016 Sep 26;3:41. eCollection 2016.


Changing Clinician Practices and Attitudes Regarding the Use of Antiretroviral Therapy for HIV Treatment and Prevention.

Buchacz K, Farrior J, Beauchamp G, McKinstry L, Kurth AE, Zingman BS, Gordin FM, Donnell D, Mayer KH, El-Sadr WM, Branson B; HPTN 065 Study Team.

J Int Assoc Provid AIDS Care. 2017 Jan/Feb;16(1):81-90. doi: 10.1177/2325957416671410. Epub 2016 Oct 5.


Increased Antiretroviral Therapy Use and Virologic Suppression in the Bronx in the Context of Multiple HIV Prevention Strategies.

Hanna DB, Felsen UR, Ginsberg MS, Zingman BS, Beil RS, Futterman DC, Strickler HD, Anastos K.

AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):955-963. Epub 2016 Mar 17.


Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders.

Bednasz C, Luque AE, Zingman BS, Fischl MA, Gripshover BM, Venuto CS, Gu J, Feng Z, DiFrancesco R, Morse GD, Ma Q.

Curr Vasc Pharmacol. 2016;14(3):280-7.


Increased HIV testing among hospitalized patients who declined testing in the emergency department.

Felsen UR, Cunningham CO, Zingman BS.

AIDS Care. 2016;28(5):591-7. doi: 10.1080/09540121.2015.1120268. Epub 2015 Dec 11.


Unknown HIV Status in the Emergency Department: Implications for Expanded Testing Strategies.

Felsen UR, Bellin EY, Cunningham CO, Zingman BS.

J Int Assoc Provid AIDS Care. 2016 Jul;15(4):313-9. doi: 10.1177/2325957415586261. Epub 2015 May 21.


Development of an electronic medical record-based algorithm to identify patients with unknown HIV status.

Felsen UR, Bellin EY, Cunningham CO, Zingman BS.

AIDS Care. 2014;26(10):1318-25. doi: 10.1080/09540121.2014.911813. Epub 2014 Apr 30.


Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America.

Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA; Infectious Diseases Society of America.

Clin Infect Dis. 2014 Jan;58(1):1-10. doi: 10.1093/cid/cit757.


Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking.

Salomon A, Krachmarov C, Lai Z, Honnen W, Zingman BS, Sarlo J, Gorny MK, Zolla-Pazner S, Robinson JE, Pinter A.

Virology. 2014 Jan 5;448:363-74. doi: 10.1016/j.virol.2013.10.007. Epub 2013 Nov 12.


Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America.

Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA; Infectious Diseases Society of America.

Clin Infect Dis. 2014 Jan;58(1):e1-34. doi: 10.1093/cid/cit665. Epub 2013 Nov 13.


Apathy correlates with cognitive performance, functional disability, and HIV RNA plasma levels in HIV-positive individuals.

Shapiro ME, Mahoney JR, Zingman BS, Pogge DL, Verghese J.

J Clin Exp Neuropsychol. 2013;35(9):934-45. doi: 10.1080/13803395.2013.838941. Epub 2013 Oct 4.


Cognitive reserve protects against apathy in individuals with human immunodeficiency virus.

Shapiro ME, Mahoney JR, Peyser D, Zingman BS, Verghese J.

Arch Clin Neuropsychol. 2014 Feb;29(1):110-20. doi: 10.1093/arclin/act071. Epub 2013 Sep 9.


Sequential antiretroviral adherence measurement using electronic bottle cap monitors in a cohort of HIV-infected adults.

Shuter J, Sarlo JA, Stubbs RO, Rode RA, Zingman BS.

J Int Assoc Physicians AIDS Care (Chic). 2012 Mar-Apr;11(2):94-7. doi: 10.1177/1545109711420498. Epub 2012 Jan 5.


Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.

Ma Q, Zingman BS, Luque AE, Fischl MA, Gripshover BM, Venuto CS, DiFrancesco R, Forrest A, Morse GD.

Ther Drug Monit. 2011 Jun;33(3):309-14. doi: 10.1097/FTD.0b013e31821d3adb.


Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.

Jacobson JM, Lalezari JP, Thompson MA, Fichtenbaum CJ, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC.

Antimicrob Agents Chemother. 2010 Oct;54(10):4137-42. doi: 10.1128/AAC.00086-10. Epub 2010 Jul 26.


Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.

Jacobson JM, Thompson MA, Lalezari JP, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC.

J Infect Dis. 2010 May 15;201(10):1481-7. doi: 10.1086/652190.


Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial.

Suleiman J, Zingman BS, Diaz RS, Madruga JV, DeJesus E, Slim J, Mak C, Lee E, McCarthy MC, Dunkle LM, Walmsley S.

J Infect Dis. 2010 Feb 15;201(4):590-9. doi: 10.1086/650342.


Occurrence of selective ritonavir nonadherence and dose-staggering in recipients of boosted HIV-1 protease inhibitor therapy.

Shuter J, Sarlo JA, Rode RA, Zingman BS.

HIV Clin Trials. 2009 May-Jun;10(3):135-42. doi: 10.1310/hct1003-135.


Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.

Jacobson JM, Saag MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, Redfield RR, Fichtenbaum CJ, Zingman BS, Patel MC, Murga JD, Pemrick SM, D'Ambrosio P, Michael M, Kroger H, Ly H, Rotshteyn Y, Buice R, Morris SA, Stavola JJ, Maddon PJ, Kremer AB, Olson WC.

J Infect Dis. 2008 Nov 1;198(9):1345-52. doi: 10.1086/592169.


Withdrawal of Pneumocystis prophylaxis.

Zingman BS, Grossberg R.

AIDS. 2008 Jan 11;22(2):323-4; author reply 324. Review. No abstract available.


Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir.

Higgins N, Zingman BS, Slish J, Reichman RC, Fischl MA, Gripshover B, Tooley K, Boston N, Forrest A, Brazeau D, Catanzaro LM, DiFrancesco R, Lliguicota F, Ma Q, Morse GD.

Am J Addict. 2007 Nov-Dec;16(6):488-94.


Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.

Slish J, Ma Q, Zingman BS, Reichman RC, Fischl MA, Gripshover B, Forrest A, Brazeau D, Boston NS, Catanzaro L, DiFrancesco R, Morse GD.

Ther Drug Monit. 2007 Oct;29(5):560-5.


Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users.

DiFrancesco R, Fischl MA, Donnelly J, Zingman BS, McCance-Katz EF, Moody DE, Reichman RC, Gripshover B, Morse GD.

J Pharm Biomed Anal. 2007 May 9;44(1):188-95. Epub 2007 Feb 16.


Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.

Ma Q, Brazeau D, Zingman BS, Reichman RC, Fischl MA, Gripshover BM, Venuto CS, Slish JC, DiFrancesco R, Forrest A, Morse GD.

Pharmacogenomics. 2007 Mar;8(3):227-35.


Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application.

Keil K, Hochreitter J, DiFrancesco R, Zingman BS, Reichman RC, Fischl MA, Gripshover B, Morse GD.

Ther Drug Monit. 2007 Feb;29(1):103-9.


False-positive result from a Bayer Versant human immunodeficiency virus type 1 branched-DNA viral load assay, with a possible role for light leakage after inadequate maintenance of the analyzer.

Marinovich A, Narlieva M, Bashir M, Zingman BS, Fox A.

J Clin Microbiol. 2006 Nov;44(11):4288-9. Epub 2006 Sep 27. No abstract available.


A computerized reminder system improves compliance with Papanicolaou smear recommendations in an HIV care clinic.

Shuter J, Kalkut GE, Pinon MW, Bellin EY, Zingman BS.

Int J STD AIDS. 2003 Oct;14(10):675-80.


Cardiac surgery in the patient with human immunodeficiency virus.

Frater RW, Comacho M, Frymus M, Soeiro R, Zingman BS.

Adv Cardiol. 2003;40:219-25. No abstract available.


Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection. Adult AIDS Clinical Trials Group Study Team 295.

Fichtenbaum CJ, Zackin R, Rajicic N, Powderly WG, Wheat LJ, Zingman BS.

AIDS. 2000 May 5;14(7):845-52.


Fever after cytotoxic therapy of chronic lymphocytic leukemia.

Zingman BS.

Cancer Invest. 1999;17(4):292-5. No abstract available.


Treatment of cryptococcal meningitis.

Zingman BS.

N Engl J Med. 1997 Nov 20;337(21):1557; author reply 1557-8. No abstract available.


Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir.

Zingman BS.

N Engl J Med. 1996 Jun 20;334(25):1674-5. No abstract available.


Splenic complications in malaria: case report and review.

Zingman BS, Viner BL.

Clin Infect Dis. 1993 Feb;16(2):223-32. Review.


Invasive infections due to Candida krusei: report of ten cases of fungemia that include three cases of endophthalmitis.

McQuillen DP, Zingman BS, Meunier F, Levitz SM.

Clin Infect Dis. 1992 Feb;14(2):472-8.


Supplemental Content

Loading ...
Support Center